Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Prognostic indicators in diffuse large-cell (histiocytic) lymphoma.

M B Todd, C S Portlock, L R Farber

International Journal of Radiation Oncology, Biology, Physics

|April 1, 1986

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.

Clinical lymphoma, myeloma & leukemia·2021

Same author

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.

Leukemia & lymphoma·2016

Same author

Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2009

Same author

Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2009

Same author

Infectious disease associations in advanced stage, indolent lymphoma (follicular and nonfollicular): developing a lymphoma prevention strategy.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Same author

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007

Identifying prognostic groups in diffuse large-cell lymphoma (DHL) is crucial for personalized therapy. Age and systemic symptoms predict treatment response, while age and bone marrow involvement impact survival in DHL patients.

Area of Science:

Hematology
Oncology
Clinical Research

Background:

Diffuse large-cell lymphoma (DHL) patient stratification is challenging.
Existing staging systems like Ann Arbor have limitations for predicting DHL outcomes.
Consensus on reliable prognostic indicators for DHL is lacking.

Purpose of the Study:

To validate a predictive model for treatment response and survival in DHL patients.
To identify key prognostic variables influencing outcomes in DHL.
To establish reliable prognostic groups for diffuse large-cell lymphoma.

Main Methods:

Retrospective analysis of 86 DHL patients treated with combination chemotherapy (1976-1982).
Evaluation of prognostic variables including age, sex, symptoms, LDH, disease sites, bulk, prior therapy, Ann Arbor stage, and Lukes Collins classification.

Related Experiment Videos

Univariate analysis to determine factors predicting treatment response and overall survival.

Main Results:

Age and systemic symptoms were significant predictors of treatment response (p<0.05).
Age and bone marrow involvement significantly influenced overall survival.
Identified specific prognostic factors for diffuse large-cell lymphoma patients.

Conclusions:

Age, systemic symptoms, and bone marrow involvement are critical prognostic factors in DHL.
Further large-scale studies are needed to refine prognostic groups for DHL.
Personalized treatment strategies can be improved by understanding these prognostic indicators.